Every 10-Q that Elutia Inc. (ELUT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ELUT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELUT filings page.
Elutia Inc. reports continued operating losses as it transitions to a focused drug‑eluting biomatrix business following prior divestitures of its Orthobiologics and CIED segments. For the six months ended June 30, 2026, net sales from continuing operations were $5.5 million, with a net loss from continuing operations of $15.5 million.
Gross profit improved year over year, but higher research and development spending on next‑generation products NXT‑41 and NXT‑41x, along with ongoing litigation costs, kept total operating expenses at $17.6 million. Operating cash outflow was $16.3 million, leaving cash and cash equivalents of $19.9 million and total assets of $43.6 million at June 30, 2026.
The company carries a current revenue interest obligation of $6.4 million and a contingent legal liability of $5.6 million related mainly to FiberCel and VBM product litigation, partially offset by $3.9 million in insurance receivables. Elutia also discloses a Nasdaq notice received on August 6, 2026 that its share price has traded below the $1.00 minimum bid, triggering a 180‑day compliance period.
Elutia Inc. reported first-quarter 2026 net sales of $3.1 million, up modestly from $3.0 million a year earlier, with gross profit improving to $1.8 million from $1.4 million as cost of goods sold declined.
The company posted a net loss of $7.5 million compared with a $3.9 million loss in 2025, mainly reflecting a $1.7 million loss on revaluation of warrant liability and higher research and development spending as it advances NXT-41 and NXT-41x. Cash and cash equivalents were $28.5 million, and operating cash outflow was $7.8 million. Results also reflect discontinued operations gains tied to prior divestitures and sizable contingent liabilities and insurance receivables related to FiberCel and viable bone matrix litigation.
Elutia Inc. (ELUT) filed its Q3 2025 10‑Q, highlighting a business refocus and discontinued operations. From continuing operations, net sales were $3,323 (thousands) versus $3,662 a year ago, with gross profit of $1,853 and a loss from operations of $5,208. Net loss from continuing operations was $383 for the quarter.
The company classified its cardiac implantable electronic device business as discontinued operations and completed its sale on October 1, 2025 for up to $88 million in cash, including $80.3 million paid at closing and $8 million in escrow for twelve months. Discontinued operations posted a quarterly net loss of $3,485. Cash and cash equivalents were $4,721 at September 30, 2025, with total liabilities of $73,325 and a warrant liability of $4,030. Management believes existing cash plus CIED sale proceeds, net of SWK debt repayment, fund operations for at least one year after issuance. On November 7, 2025, Nasdaq notified Elutia of non‑compliance with the $1.00 minimum bid price, with a 180‑day compliance period.
Elutia, Inc. reported continued operating losses and significant legal and liquidity risks in its Form 10-Q. For the six months ended June 30, 2025, the company recorded a net loss of $13.5 million and an accumulated deficit of $243.1 million. Cash used in operations totaled $17.1 million year-to-date and the company expects ongoing cash outflows for the rest of 2025, raising concerns about its ability to achieve and sustain profitability.
The company completed the sale of its Orthobiologics Business (initial gain recognized of $6.0 million in 2023 and an additional $0.2 million in 2024) with potential earn-outs of up to $20 million and a $1.5 million indemnity holdback. Material litigation includes extensive FiberCel and VBM claims: the company recorded $13.3 million as a probable liability for 47 FiberCel cases and $3.7 million for VBM-related matters, with substantial settlements already paid and insurance receivables recorded. Elutia has a secured SWK loan facility with a weighted average interest rate of 12.6% for the three months ended June 30, 2025 and amended covenants requiring a minimum liquidity of $8.0 million. The company discloses substantial risks around commercialization of EluPro, supplier dependence, indemnities and contingent liabilities.